Psoriasis isn't just a skin condition. It's an autoimmune disease that can shape your mental and emotional world too.
Psoriasis—a chronic, autoimmune condition that causes inflammation of the skin, often in the form of thick discolored areas covered with scales—is unpleasant enough on its own. But people with ...
News-Medical.Net on MSN
Study reveals key role of sugars in immune cell movement during psoriasis
New research has updated our understanding of how sugars, known as glycans, help immune cells move into skin in the ...
Childhood emotional trauma significantly elevates psoriasis risk by disrupting immune responses, new research reveals. Early ...
Psoriasis is an autoimmune condition that results in red, scaly skin patches. Food choices cannot cure psoriasis, but fried foods, processed meats and sugary beverages may make the symptoms worse.
The only recommendation for management of this disease is prescription creams. However, a new study has discovered that switching to a Mediterranean diet could provide significant relief, according to ...
The New Times on MSN
Skin conditions: Psoriasis patients speak out on stigma and neglect
Valentine Murekatete, a 31-year-old resident of Kibagabaga, began noticing unusual itching on her skin in 2015. What started as a minor irritation soon turned into a burning sensation that spread in ...
Psoriasis is not "just a skin disease" as it has been misunderstood for a long time. It is a lifelong, immune-mediated condition that affects the entire body. The body's immune system triggers an ...
What Is the Auspitz Sign? Auspitz sign is a distinctive mark seen when a skin plaque has been removed. Plaques (also called scales) are common in plaque psoriasis, but people with Darier′s disease and ...
Psoriasis is a chronic, inflammatory skin condition, but its effects go well beyond the skin. While it’s often recognized for its itchy, scaly patches, experts believe that the root causes of ...
More than 50% of patients with psoriasis are eligible for systemic treatment, and nearly 90% would switch to an effective oral therapy with a favorable safety profile.
Icotrokinra, a targeted oral peptide that selectively binds the interleukin-23 receptor, is under investigation for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results